Heterogenous treatment effects : secrets for a reliable treat-to-target trial? by Guzik, Tomasz
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Heterogenous treatment effects: secrets
for a reliable treat-to-target trial?
Tomasz J. Guzik1,2*
1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK; and 2Department of Internal and Agricultural Medicine, Jagiellonian University, Collegium
Medicum, ul. Skarbowa 1, 31-101, Krakow, Poland
Commentary on ‘Detecting heterogeneous treatment effects
to guide personalized blood pressure treatment: a modeling
study of randomized clinical trials’ by Basu et al., Ann Intern
Med, 2017.1
Over three decades ago Prof Salim Yusuf, Professor Sir Rory Collins and
Professor Sir Richard Peto have written the memorable motto to the cur-
rent clinical research reminding us to ‘always ask important questions and
answer them reliably. . .’.2 Although in the era of large randomized clinical
trials (RCTs), we believe that we have really understood the key to gaining
truly reliable clinical answers, recent clinical trials of hypertension, have
however taught us the ‘lessons of humility’.3 Over the past year, we have
seen an explosion of commentaries and interpretations explaining
discrepancies in recent blood pressure target trials including inconclusive
ACCORD-BP and SPS3 trials and robustly favorable SPRINT trial.3 Simple
chance, differences in age, effects of diabetes, or chronic kidney diseases,
differences in outcome definitions or BP measurement techniques have all
been discussed as causes for discrepancy between results. As clinicians, we
are left with a dilemma how to implement these divergent results into our
everyday decisions. As clinical researchers, we are left with an important
question—how to design a treat-to-target clinical trial that will reliably
guide future clinical practice. Finally, as basic researchers—we are facing a
dilemma—how to use results of these trials to generate new hypothesis
and design experiments, that will have high chance of translation. These
are essential questions in cardiovascular research, and recent theoretical
modeling approaches using microsimulation provide us with important
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suggestions.1 Treat-to-target trials are very attractive for clinical audiences,
because patients are randomized to specific blood pressure goal, which
brings them close to clinical situation. Discrepancies between SPRINT and
ACCORD conclusions, in spite of their robust designs, have however
brought up an important point, that such treat-to-target design may not
have sufficient power to examine heterogeneous treatment effects
(HTEs), as these occur after randomization.4,5 HTEs encompass differen-
tial patient response to specific therapeutic decisions, with some patients
responding differently to others. Although classical subgroup analysis is
used to address this problem, it does not seem sufficient, as evidenced by
comparison of SPRINT and ACCORD trials. Using microsimulation, theo-
retical modeling, Basu et al.1 have recently shown that increasing harm at
low diastolic BP (<70 mmHg) and diminishing benefit with each additional
BP agent, with no benefit >3 agents, may explain differences in the results
of SPRINT and ACCORD. Surprisingly, subgroup analysis in these trials
failed to show significant interactions among selected pre-specified
groups.6 Thus, assumptions that, if subgroup analysis of a successful trial
fails to show HTEs, then results can be safely generalized to whole trial
population may not be correct and lead to mistakes. It is essential to
remain very conscious of HTEs and assess the statistical power individual
study design has, to detect those. According to Basu et al.,1 classical treat-
to-target design has only 5% statistical power to detect HTEs in spite of
very large trial population of >20 000. This is largely associated with the
heterogeneity of interventions to achieve target, that is then oversimplified
in analysis of aggregate outcomes among intensive treatment and control
groups. Although this is a problem in all in treat-to-target trials, such patho-
physiological and pharmacological heterogeneity is particularly characteris-
tic for hypertension. In blood pressure treatment trials, we experience
within patient heterogeneity and between individual heterogeneity.
Differential treatment adherence and response rate is linked to pathophy-
siological basis of disease heterogeneity including clinical factors baseline
CVD risk, blood pressures or co-morbidities and pathophysiologic mecha-
nisms involving central nervous system, vascular, renal, cardiac, and
immune components.7 Moreover, within-patient heterogeneity with time
on individual treatment is also possible and rarely accounted for.8
Additional considerations unfold over time of a treat to target study, and
would favour individualized sequence of randomized treatments.
1. What is the solution?
The Sequential Multiple Assignment Randomized Trial (SMART) research
design has been developed explicitly for the purpose of building optimal
adaptive interventions by providing answers to clinical questions with
complex multifactorial context, as seen for example in hypertension.
Indeed, Basu et al.1 conclude that a trial with sequential randomization to
more intensive therapy would have greater than 80% power (as opposed
to 5% power in treat-to-target design) even with much smaller sample
size. Although the study of Basu et al. suffers from some weaknesses and
will benefit from additional validation of the model using patient level data,
which have now become available from SPRINT, we have to remain very
conscious of HTEs when designing a clinical studies in hypertension and
when interpreting results. The SMART design of future trials also fits the
current need for guiding the development of personalized targeted cardio-
vascular therapies.9,10 In the case of hypertension, the multi-drug treat-
ment seems to be a major cause of the HTEs; therefore, it is critical to
provide a random assignment to addition of each additional agent during
intensification of treatment. This also corresponds much more closely to
clinical sequential decision-making in the treatment of hypertension
depending on the individual heterogeneity in response to treatment.8
Although analysis of such trial may be challenging, it is a form of a factorial
experimental design, and it allows to truly examine effects of treatment
intensification on the way to reaching the blood pressure target.
Thus, considering increasing need of personalized therapies and in
pursuit of reliable identification of optimal treatment targets we are likely
to use SMART designs in the future and we need to take into account
complex heterogenous treatment effects. However, we need to remem-
ber that the overarching aim of SMART designs is different to standard
RCTs. SMARTs have been created to construct a high-quality adaptive
intervention based on data and modeling, while the overarching aim of
an RCT is to evaluate an already-existing intervention versus placebo/
control treatment.8 Increased power to detect heterogeneity of treat-
ment responses may, however, increase scope and usefulness of SMART
design for treat-to-target studies in cardiovascular research and in partic-
ular in hypertension.
2. Implications for a basic scientist
RCTs are a key element of translation of basic findings to clinical practice.
We should note, that the results of the study of Basu et al., relate to a
specific type of trials—the treat-to-target trials. They however bring our
attention to the fact of heterogeneity of clinical responses in such trials,
that may reflect limitations in translating basic science findings in RCTs.
As we see from microsimulation of SPRINT and ACCORD, in contrast
to our basic models, such heterogeneity cannot be easily controlled in
simple study designs. Using pure models, in which key variables are con-
stant, is essential for establishment of causal associations and gaining
mechanistic insights. The choice of study model is essential for ability to
generalize of our basic results to complex clinical settings. A potentially
valuable transitional stage could include experiments using fresh human
tissues (or organoid cultures) to verify key findings in a more heteroge-
nous, although still controlled, setting. For example, studies in human
blood vessels may represent such valuable model which inherently
includes HTEs.11,12
Moreover, as most HTEs are pathophysiology based, there is a need
to identify the key pathophysiological determinants in basic science
experiments, prior to embarking on an expensive and challenging route
of RCT translational study. Thus knowledge of pathophysiology is essen-
tial for informed design of SMART trial.
Results of this microsimulation are also important to a basic scientist,
specifically, within the field of hypertension. In most hypertension-
related basic studies we rely on telemetric blood pressure measurement
as a major endpoint. The unresolved discrepancy between SPRINT and
ACCORD trials makes it questionable, whether this is the best approach
in basic studies of novel therapeutic interventions in hypertension. For
example, numerous molecules alter vascular function without affecting
blood pressure increase,13 which in line with ACCORD would be very
important and in the light of SPRINT, less essential. Thus understanding
heterogenous treatment effects in these trials will help us define in which
patients, results of basic studies may be particularly applicable. This can
aid better design of next RCTs. It may also help us chose the best study
model.
In conclusion, as basic as well as clinican scientists, we should ensure if
pathophysiological and pharmacological heterogeneity has been suffi-
ciently accounted for in a trial, if the key HTEs have been identified and
what was the power of the design to detect those. It turns out, that sim-
ple subgroup analyses presented in the RCTs may not be sensitive
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.enough, and hence a need to seek for analysis of HTEs. Finally, if signifi-
cant HTEs are seen, which model will most reliably represent those in
our ‘from bench to bedside and . . .back’ studies.
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